Latigo Biotherapeutics (NASDAQ:LTGO) Trading 4.9% Higher – Still a Buy?

Posted by Alphonse Anthony on Aug 28th, 2026

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report)’s share price rose 4.9% during trading on Wednesday . The stock traded as high as $23.75 and last traded at $23.68. 37,816 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 223,493 shares. The stock had previously closed at $22.57.

Analyst Ratings Changes

Separately, Wall Street Zen raised Latigo Biotherapeutics to a “hold” rating in a report on Saturday, August 15th.

View Our Latest Report on Latigo Biotherapeutics

Latigo Biotherapeutics Trading Up 3.6%

Insider Transactions at Latigo Biotherapeutics

In other Latigo Biotherapeutics news, major shareholder Foresite Capital Management V, purchased 140,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the insider directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James B. Tananbaum purchased 140,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the transaction, the director directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Latigo Biotherapeutics

(Get Free Report)

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.